Hemophilia Perspectives: Current Insights on the Evolution of Gene Therapy

Friday Satellite CME Dinner Symposium preceding the 60th American Society of Hematology Annual Meeting & Exposition (ASH)

 Friday, November 30, 2018

Registration & Dinner: 6:00 pm - 6:30 pm PT

Presentation: 6:30 pm - 8:00 pm PT

Manchester Grand Hyatt San Diego
San Diego, CA
GH - Grand Hall A

Target Audience
This CME satellite symposium is designed to meet the educational needs of HCPs and their support teams, as well as other clinicians who diagnose, treat, and counsel patients with hemophilia

Statement of Need/Program Overview 
Because the advancements in gene therapy indicate that hemophilia may be curable, it is essential that HCPs understand the complex nature of the genetics of hemophilia, how gene therapies work in general, and the evidence to date regarding their effectiveness in persons with hemophilia. 

Educational Objectives
After completing this activity, the participant should be better able to:

  • Discuss the genetic complexity underlying hemophilia
  • Describe the potential benefits of undergoing genetic diagnostic testing for hemophilia
  • Discuss the essential aspects of gene therapy and gene editing in the treatment of persons with hemophilia
  • Review new and emerging gene therapy‐based options available for the treatment of hemophilia

Faculty Chair
Michael Recht, MD, PhD
Professor of Pediatrics and Medicine
Director, The Hemophilia Center
Oregon Health & Science University
Portland, OR  

Faculty Presenters
Tammuella Chrisentery Singleton, MD
Assistant Professor of Medicine and Pediatrics Section Chief, Pediatric
Hematology/Oncology Louisiana Center for Bleeding and Clotting Disorders
Tulane University School of Medicine
Louisiana Center for Bleeding and Clotting Disorders
New Orleans, LA

Gerald Dolan, MD
Director, St Thomas’ Haemophilia Centre and Head, Haemostasis & Thrombosis Service
Guy’s and St Thomas’ Hospital
London, UK

Program Agenda 

6:00PM to 6:30PM
Registration & Dinner
6:30PM to 6:40PM
6:40PM to 6:55PM
Review of the issues associated with a genetic diagnosis and the utility of genetic testing
6:55PM to 7:10PM
Case presentation
7:10PM to 7:35PM
Panel Discussion about the essential aspects of gene therapy and gene editing, including new and emerging options
7:35PM to 7:50PM

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Educational Concepts in Medicine. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.5 contact hours.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within 3 weeks.

Fee Information
There is no registration fee for attending this symposium; however, seating is limited. Preregistration does not guarantee seating. We do recommend arriving at the satellite symposium location early.

Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact The Blood CME Center Support Center prior to the live event at cme@bloodcmecenter.org

Disclosure of Conflicts of Interest
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Michael Recht, MD, PhD

Consulting Fees: Genentech, Kedrion, Pfizer, and uniQure

Contracted Research:Bioverativ, Genentech, NovoNordisk, and Shire

Tami Singleton, MD

Consulting Fees: Novo Nordisk, Shire, Bayer, Grifols, Genentech, Bioverativ, Biomarin and CSL Behring

Fees for NON-CME/CE Services Received Directly from a Commercial Interest or their Agents: Novo Nordisk, Shire, Genentech, Grifols and CSL Behring

Gerald Dolan, MD

Consulting Fees: Shire, Novo Nordisk, Pfizer, Bayer, Roche, and Spark Therapeutics, Inc. Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Shire, Pfizer, Roche and Novo Nordisk

Contracted Research: Pfizer, Bayer, Novo Nordisk. Biomarin, Spark Therapeutics, Freeline, and Roche

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
PIM Clinical Reviewers

Have no real or apparent conflicts of interest to report.

ECM: Patrick J. Crowley, MBA, Partner/CEO; Jodi Andrews, BS Partner/COO; Christine Blood, PhD, Medical Writer Have no real or apparent conflicts of interest to report.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Commercial Support
This educational activity is supported by an independent medical educational grant from Spark Therapeutics, Inc.

Click the “Continue Registration” button to indicate you have reviewed the CME/CE information for this activity.
Continue Registration